SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2019-04-18
Target enrollment:
Participant gender:
Summary
This is an open label, single-arm, multi-center, phase II study of SHR-1210 in metastatic
colorectal cancer patients with the recurrent lesion(s) post-surgery or the untreated mCRC.
SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1).BP102 is a
humanized recombinant monoclonal IgG1 antibody.
The primary objective of this study is to investigate the safety and efficacy of the subjects
who given the combination therapy.